Intravitreal voriconazole for the treatment of cryptococcus neoformans endogenous endophthalmitis

7Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Background: Cryptococcus neoformans is an encapsulated yeast that can cause fungemia and, in rare instances, lead to endogenous fungal endophthalmitis. No standard of care has been established to treat fungal endophthalmitis when systemic antifungal treatment fails to resolve the intraocular infection. Intravitreal voriconazole has been used for the treatment of fungal endophthalmitis caused by a broad range of fungal pathogens, and a limited number of reports have shown the efficacy of using intravitreal voriconazole for C neoformans endophthalmitis. We report a case of endogenous fungal endophthalmitis caused by C neoformans that was responsive to intravitreal voriconazole. Case Report: A previously healthy 57-year-old male diagnosed with primary neuroendocrine lung tumor developed endogenous endophthalmitis from C neoformans. The endophthalmitis was resistant to intravenous amphotericin B treatment but was responsive to intravenous fluconazole in one eye and was apparently more responsive to intravitreal voriconazole in the other eye. Conclusion: Intravitreal voriconazole should be considered for the treatment of cryptococcal endophthalmitis.

Cite

CITATION STYLE

APA

Haider, A. A., Gallagher, J. R., Johnson, J. S., & Benevento, J. D. (2020). Intravitreal voriconazole for the treatment of cryptococcus neoformans endogenous endophthalmitis. Ochsner Journal, 20(3), 319–322. https://doi.org/10.31486/toj.19.0043

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free